Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - Review of the literature

European Journal of Medical Research

Volumn 16, Issue 4, 2011, Pages 145-152

  Karthaus, Meinolf ^a  

^a Klinikum Neuperlach   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; MICAFUNGIN; PLACEBO; POSACONAZOLE; PROTON PUMP INHIBITOR; VORICONAZOLE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIFUNGAL SUSCEPTIBILITY; BLOOD LEVEL; BRAIN TOXICITY; CANDIDIASIS; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL DISEASE; GOLD STANDARD; GRAFT VERSUS HOST REACTION; HUMAN; HYPOKALEMIA; INFECTION PREVENTION; INJECTION SITE REACTION; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; MUCOSA INFLAMMATION; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL; SURVIVAL RATE; SYSTEMIC MYCOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL IMPAIRMENT; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; BRAIN DISEASE; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RESPONSE; EVIDENCE BASED PRACTICE; INFUSION RELATED REACTION; LUNG ASPERGILLOSIS; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RISK FACTOR; VISUAL DISORDER;

EID: 79955852485     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-16-4-145     Document Type: Review

References (56)

1. Lehrnbecher T, Frank C, Engels K, et al. Trends in the postmortem epidemiolgy at a university hospital. J Infect. 2010 Sep;61(3):259-65
2. Stevens DA, Kan VL, et al. Practice guidelines for diseases caused by Aspergillus. Clin. Infect. Dis. 2000; 30:696-709.
3. Rex JH, Walsh TJ, Anaissie EA. Fungal infections in iatrogenically compromised hosts. Adv. Intern. Med. 1998; 43:321-371
4. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin. Infect. Dis. 2000; 30:662-678.
5. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008 Jun 15;46(12):1813-21.
6. Maertens J, Van Eldere J, Verhaegen J, et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infec Dis. 2002 186:1297-1306 (Pubitemid 35193008)
7. Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood. 2003 May 1;101(9):3365-72. Epub 2002 Aug 29.
8. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ. 2001 Mar 10;322(7286):579-82. (Pubitemid 32234532)
9. Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Böhme A, Ruhnke M, Buchheidt D,et al. Treatment of invasive fungal infections in cancer patients - recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2009 Feb;88(2):97-110.
10. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical practice guidelines of the IDSA. CID 2008; 46: 327-60. (Pubitemid 351265310)
11. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999 Mar 11;340(10):764-71.
12. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997 Sep;98(3): 711-8. (Pubitemid 27386554)
13. Walsh TJ, Teppler H, Donowitz GR,et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004 Sep 30;351(14):1391-402.
14. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845-851
15. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545-1552
16. Marr KA, Seidel K, Slavin MA,et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000 Sep 15;96(6):2055-61.
17. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007 Jan 25;356(4):348-59. (Pubitemid 46148777)
18. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007 Jan 25;356(4):335-47. Erratum in: N Engl J Med. 2007 Jul 26;357(4):428.
19. van Burik JA; Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA; Hiemenz JW; Satoi Y, Lee JM, Walsh TJ; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004 Nov 15;39(10):1407-16
20. Penack O, Schwartz S, Martus P, Reinwald M, Schmidt-Hieber M, Thiel E, Blau IW. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006 Aug;17(8):1306-12 (Pubitemid 44288223)
21. Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC, Ruijgrok EJ, Löwenberg B, Vulto A, Lugtenburg PJ, de Marie S. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46(9): 1401-8
22. Vehreschild JJ, Böhme A, Buchheidt D, et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect. 2007 Nov;55(5):445-9. (Pubitemid 47628350)
23. Wingard JR, Carter SL, Walsh TJ, et.al. Blood an Marrow Transplant Clinical Trials Network. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116(24): 5111-8
24. Prentice AG, Glasmacher A, Djulbegovic B. In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treamtent of hematological malignancy. Br J Haematol 2005; 131(1):22-8
25. Cornely OA, Böhme A, Buchheidt D, et al.. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2009; 94(1):113-22
26. Karthaus M, Hentrich M. Wait and see or rush and switch? New questions for the management of patients with febrile neutropenia receiving antifungal prophylaxis. Mycoses. 2011 Jan; 54 (Suppl 1): 1-6
27. Krishna G, AbuTarif M, Xuan F, et al. Pharmakokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myleodysplastic syndrome. Pharmacotherapy. 2008; 28(10): 1223-32.
28. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother. 2006 Feb;50(2): 658-66. (Pubitemid 43190980)
29. Lipp HP. Posaconazole:clinical pharmacokinetics and drug interactions. Mycoses. 2011 Jan(Suppl 1): 32-8.
30. Shields RK, Clancy CJ, Vadnerkar A, et al. Posaconazole serum concentrations among cardiothoracic transplant reciepients: Factors influencing levels and correlation with clinical response. Antimicrob Agents Chemother. 2010 Dec 2010 [Epub ahead of print]
31. Kohl V, Müller C, Cornely OA, et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother. 2010 Jan;54(1):207-12.
32. Lebeaux D, Lanternier F, Elie C, et al. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother. 2009 Dec;53(12): 5224-9. Epub 2009 Sep 14.
33. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007 Apr;39(7):425-9. (Pubitemid 46487308)
34. Lekakis LJ, Lawson A, Prante J, et al. Fatal rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis: two cases and review of the literature. Biol Blood Marrow Transplant. 2009 Aug;15(8): 991-5..
35. Mousset S, Bug G, Heinz WJ, et al. Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation. Transpl Infect Dis. 2010 Jun;12(3): 261-4
36. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002 Aug 8;347(6):408-15. (Pubitemid 34851833)
37. Karthaus M. Voriconazole versus amphotericin B for invasive aspergillosis. N Engl J Med. 2002 Dec 19;347(25): 2080-1. (Pubitemid 35461670)
38. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis using voriconazole treatment. Blood 2005; 106(8):2641-5. (Pubitemid 41510735)
39. Pascual A, Calandra T, Bolay S, et l. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcome. Clin Infec Dis 2008; 46(2):201-11
40. Trifilio S, Pennick G, Pi J, Zook J, et al. Monitoring voriconzole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell recipients. Cancer 2007; 109(8):1532-5. (Pubitemid 46595688)
41. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007 May 15;44(10):1289-97. (Pubitemid 46717290)
42. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004 Dec 1;39(11):1563-71. Epub 2004 Nov 9. (Pubitemid 39578526)
43. Viscoli C, Herbrecht R, Akan H, et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother. 2009 Dec;64(6):1274-81. Epub 2009 Oct 19.
44. Mora-Duarte J, Betts R, Rotstein C, et al.Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002 Dec 19;347(25):2020-9. (Pubitemid 35461658)
45. Betts R, Glasmacher A, Maertens J, et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer. 2006 Jan 15;106(2):466-73. (Pubitemid 43100459)
46. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.Lancet. 2007 May 5;369(9572):1519-27.
47. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007 Oct 1;45(7):883-93. (Pubitemid 47580382)
48. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007 Jun 14;356(24):2472-82. (Pubitemid 46919773)
49. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006 Nov;53(5):337-49. (Pubitemid 44524711)
50. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007 Jan 1;44(1):2-12. (Pubitemid 44968977)
51. Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of pulmonary aspergillosis in patients with hematological malignancies, chronic granulomatous disease or AIDS. Clin Infect Dis. 2010; 33(8):e83-90.
52. Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis. 2004 Aug 1;190(3):641-9. (Pubitemid 38982107)
53. Maertens JA, Klont R, Masson C, et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis. 2007 May 15;44(10): 1329-36. (Pubitemid 46729195)
54. Rickerts V, Böhme A, Viertel A, et al. Cluster of pulmonary infections caused by Cunninghamella bertholletiae in immunocompromised patients. Clin Infect Dis. 2000 Oct; 31(4):910-3. (Pubitemid 32299346)
55. Kontoyiannis DP, Ratanatharathorn V, Young JA, et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis. 2009 Feb;11(1):89-93.
56. Thomas A, Korb V, Guillemain R, et al. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis. J Clin Pharm Ther. 2010 Feb;35(1):49-53.